US Physical Therapy
USPH Small CapHealthcare · Medical Care Facilities
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
US Physical Therapy en bref
US Physical Therapy (USPH) is currently trading at 68,71 € with a market capitalization of 1,0 Md €. The trailing P/E ratio stands at 158.12x, with a forward P/E of 23.13x. The 52-week range spans from 50,57 € to 81,25 €; the current price is 15.4% below the yearly high. Year-over-year revenue growth stands at +7.9%. The net profit margin stands at 4.41%.
💰 Dividende
US Physical Therapy pays an annual dividend of 1,58 € per share, representing a yield of 2.3%. The payout ratio stands at 362%. The elevated payout ratio reflects a mature dividend policy.
📊 Avis des analystes
6 analystes évaluent US Physical Therapy (USPH) au consensus : Acheter. L'objectif de cours moyen est de 81,40 €, soit un potentiel de +18.48% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 76,48 € à 86,90 €.
US Physical Therapy : la thèse d'investissement en détail
US Physical Therapy (USPH) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 18.48% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
With a net margin of just 4.41%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
À surveiller
- The forward P/E of 23.13x is meaningfully below the trailing 158.12x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Rendement du dividende solide de 2.3%
- Bilan solide avec faible endettement (D/E 46.35)
- Free cash flow positif
- –Faible rentabilité (marge 4.41%)
- –Multiple de valorisation élevé (P/E 158.12x)
- –Actuellement jugée surévaluée
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (7.95%).
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy US Physical Therapy?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news